Science from the Dan Barouch Lab at @BIDMCHealth and @harvardmed’s Center for Virology & Vaccine Research. RTs ≠ endorsements
Joined July 2020
- Tweets 408
- Following 230
- Followers 1,503
- Likes 1,939
79 Photos and videos
Pinned Tweet
5 Sep 2023
New data from the Barouch Lab on BA.2.86.
1. NAb responses to BA.2.86 were lower than to BA.2 but were comparable or higher than to current circulating variants.
2. NAb titers to all variants including BA.2.86 increased following XBB infection
22
107
344
864,561
Barouch Lab retweeted
13 Dec 2025
Long COVID involves activation of proinflammatory and immune exhaustion pathways @NatImmunol @BarouchLab
nature.com/articles/s41590-0…
3
15
1,810
Barouch Lab retweeted
1 Nov 2025
Vaccines for #H5N1 based on either mRNA or an adenovirus vector can shield macaques from the virus when delivered via an intramuscular prime and a mucosal boost regimen, according to new experiments. @lasradoN @BarouchLab @BIDMC_CVVRTrial scim.ag/3KUJqll
2
15
1,853
Barouch Lab retweeted
17 Oct 2025
Vaccines for #H5N1 based on either mRNA or an adenovirus vector can shield macaques from the virus when delivered via an intramuscular prime and a mucosal boost regimen, according to new experiments. @lasradoN @BarouchLab @BIDMC_CVVRTrial scim.ag/3KUJqll
1
3
11
1,063
Barouch Lab retweeted
17 Oct 2025
Excited to share our work on mucosal vaccines against HPAI #H5N1 @ScienceTM @BarouchLab!! We show how mRNA and adenovirus vaccines provide protection against H5N1, with mucosal adenovirus delivery providing near complete protection!
science.org/doi/10.1126/scit…
1
4
226
Barouch Lab retweeted
Was informed @BarouchLab is still actively recruiting participants in the New England area--
#LongCovid
*Not to be used as medical advice or diagnosis. ILCA does not endorse any trial or sponsor.
28 Mar 2025
Long COVID or PASC may be characterized by persistent activation of chronic inflammatory pathways, affecting millions of Americans. Our latest clinical trial focuses on repurposing Abrocitinib to reduce symptoms in people with Long COVID. Our trial is currently recruiting! (1/2)
2
1
389
15 Oct 2025
RT @LabWaggoner: Mucosal delivery of a rhesus adenovirus–vectored H5N1 influenza vaccine confers protection against lethal challenge in cyn…
2
Barouch Lab retweeted
28 Mar 2025
Long COVID or PASC may be characterized by persistent activation of chronic inflammatory pathways, affecting millions of Americans. Our latest clinical trial focuses on repurposing Abrocitinib to reduce symptoms in people with Long COVID. Our trial is currently recruiting! (1/2)
3
17
25
8,739
Barouch Lab retweeted
15 Sep 2025
Published today in @CellCellPress: A new mRNA #TB vaccine developed at @BIDMChealth’s CVVR by @BarouchLab protected mice better than the century-old BCG shot — reducing infection, slowing spread & lowering lung bacterial levels. 🧬💉 dlvr.it/TN5Lmp
1
1
2
157
Barouch Lab retweeted
15 Sep 2025
Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines @BarouchLab @CellCellPress @BIDMChealth @harvardmed 🇺🇸
cell.com/cell/fulltext/S0092…
1
3
667
Barouch Lab retweeted
20 Aug 2025
Beautiful paper from @BarouchLab looking at H5N1 pathogenesis in rhesus & cynomolgus macaques (link in replies).
Dan presented some of this work in Feb at a meeting at Scripps & the mortality data was striking. H5N1 is really pathogenic in macaques, but in species-specific ways.
1
7
20
3,738
Barouch Lab retweeted
9 Jul 2025
Mucosal delivery and gene-based vaccines can both enhance boost responses for influenza vaccination in cynomolgus macaques over available vaccines
science.org/doi/10.1126/scit…
@ScienceTM @BarouchLab
1
8
873
Barouch Lab retweeted
11 Jul 2025
mRNA or adenovirus flu vaccine boosters produce strong immune responses against H1N1 and match the efficacy of a live-attenuated booster in macaques, supporting their potential as a more flexible platform for #influenza vaccines. @BarouchLab @BIDMChealth scim.ag/45Zjb5M
2
8
1,157
Barouch Lab retweeted
28 Mar 2025
#LongCovid has impaired millions of people, with no cure on the horizon. @BIDMC_CVVRTrial has launched a trial to test Abrocitinib to alleviate LC symptoms. If you’re around Boston, see if you qualify! 👇@thephysicsgirl
@ImmunoFever @EricTopol @VirusesImmunity @LCCampaign
28 Mar 2025
Long COVID or PASC may be characterized by persistent activation of chronic inflammatory pathways, affecting millions of Americans. Our latest clinical trial focuses on repurposing Abrocitinib to reduce symptoms in people with Long COVID. Our trial is currently recruiting! (1/2)
1
8
15
1,651
28 Mar 2025
Long COVID or PASC may be characterized by persistent activation of chronic inflammatory pathways, affecting millions of Americans. Our latest clinical trial focuses on repurposing Abrocitinib to reduce symptoms in people with Long COVID. Our trial is currently recruiting! (1/2)
3
17
25
8,739
28 Mar 2025
Email BIDMC-CVVRTRIALS@bidmc.harvard.edu or call 617-735-4610 to inquire. Additional information can also be found here [clinicaltrials.gov/study/NCT…]. (2/2)
5
3
402
Barouch Lab retweeted
7 Jan 2025
I'm very excited to share our recent paper describing the antigenic relationship of SARS-CoV-2 variants in Nonhuman primates for the first time.
@BarouchLab @annetzl @lasradoN @JanineKimpel @Cambridge_Uni @MedUniInnsbruck
cell.com/cell-reports/fullte…
1
3
8
468
Barouch Lab retweeted
25 Oct 2024
It took some time for this to come out, but I am glad it's out now @ScienceTM!!! It was a huge effort by our team @BarouchLab @airisyc @CamilleRMazurek and many more to evaluate mucosal immune responses, 4 years into the COVID-19 pandemic.
science.org/doi/10.1126/scit…
3
8
27
4,589
Barouch Lab retweeted
3 Oct 2024
This study shows that mpox antibody responses generated by the MVA-BN vaccine wane significantly within 6 to 12 months, potentially leaving individuals vulnerable to reinfection.
ja.ma/47UtpTG
5
7
12,183
Barouch Lab retweeted
3 Oct 2024
New data from @BIDMChealth @BarouchLab suggests that protective immunity against #Mpox may have waned in previously vaccinated individuals and that boosting may be required to maintain robust protection
3 Oct 2024
This study shows that mpox antibody responses generated by the MVA-BN vaccine wane significantly within 6 to 12 months, potentially leaving individuals vulnerable to reinfection.
ja.ma/47UtpTG
3
4
842
Barouch Lab retweeted
17 May 2024
Ahead of #HIVVaccineAwarenessDay JIAS has published a new viewpoint, “The potential of broadly neutralizing antibodies for HIV prevention”.
Read it here: bit.ly/4bHHTHj #HVAD
@huubgelderblom @BarouchLab
5
13
1,001